![[SIGN thistle header]](../../../images/page-header-template.jpg)
Antithrombotic
Therapy
References
1 US Department
of Health and Human Services. Agency for Health Care Policy and Research.
Acute pain management: operative or medical procedures and trauma. Rockville
(MD): The Agency; 1993. Clinical Practice Guideline No.1. AHCPR Publication
No. 92-0023. p.107.![[Back]](../../../images/refback.gif){kind=small}
2 CRAG. Thrombolytic
therapy in the early treatment of acute myocardial infarction: consensus
statement. Scottish Office. Edinburgh, HMSO 1991.[section
1.1] [section 1.6]
[section 5.1] [section
5.1.2]
3 Scottish
Health Service Advisory Council. The management of patients with stroke:
a report of a working group of the National Medical Advisory Committee.
Edinburgh: HMSO 1994.
4 National
Medical Advisory Council. Vascular surgery services. Edinburgh: HMSO 1994
5 Scottish
Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism.
Edinburgh: SIGN 1995. (SIGN publication no. 2.) [section
1.1] [section 1.5] [table
2] [section 1.7] [section
2.1] [section 2.2] [section
2.8] [section 2.10] [section
5.1.3] [section 6.2] [section
7] [section 13]
6 Fourth
American College of Chest Physicians Consensus Conference on Antithrombotic
Therapy. Chest 1995 Oct;108(4 Suppl):225S-522S.
[section 1.2] [section
1.3] [section 1.4] [section
1.5] [section 3.2]
[section 4.7] [section
5.1]
7 Antiplatelet
Trialists' Collaboration. Collaborative overview of randomised trials of
antiplatelet therapy: I. Prevention of death, myocardial infarction, and
stroke by prolonged antiplatelet therapy in various categories of patients.
BMJ 1994; 308: 81-106. [published erratum appears in BMJ 1994; 11; 308:
1540. An unpublished update, presented at the Antithrombotic Trialists'
Collaboration 1997 meeting, was also consulted.][section
1] [section 2] [section
3.2] [section 5.1] [section
5.2] [section 5.3] [section
5.4] [section 6.1] [section
6.3] [section 7.1.1] [section
7.2.2] [section 7.2.3]
[section 11]
8 Antiplatelet
Trialists' Collaboration. Collaborative overview of randomised trials of
antiplatelet therapy: II. Maintenance of vascular graft or arterial patency
by antiplatelet therapy. BMJ 1994; 308: 159-68.
[section 1] [section
5] [section 6.1]
[section 6.3] [section
9] [section
11.1.1] [section 11.1.2]
9 Eccles
M, Freemantle N, Mason J and the North of England Aspirin Guideline Development
Group. North of England evidence based guideline development project: guideline
on the use of aspirin as secondary prophylaxis for vascular disease in primary
care. BMJ 1998; 316: 1303-9.
[section 1] [section
5.1] [section 5.2]
[section 5.3] [section
5.4] [section 6.3]
[section 7.2.2] [section
11.1.1] [section
11.1.2]
10 Atrial
Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic
therapy in atrial fibrillation. Analysis of pooled data from five randomized
controlled trials. Arch Intern Med 1994; 154: 1449-57. [Erratum appears
in Arch Intern Med 1994; 154: 2254.][section
1.4] [section 1.5]
[section 3.1] [section
3.2] [section 3.3.1] [section
3.3.2] [section 3.3.4] [section
3.4] [section 4.4] [section
5.1.3]
11 Atrial
Fibrillation Investigators. The efficacy of aspirin in patients with atrial
fibrillation. Analysis of pooled data from 3 randomised trials. Arch Intern
Med 1997; 157: 1237-40.[section
1.4] [section 1.5]
[section 3.2] [section
3.3.1] [section
3.3.2] [section 3.4]
[section 4.4] [section
5.1.3]
12 Gage
BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and
aspirin for prophylaxis of stroke in patients with non-valvular atrial fibrillation.
JAMA 1995; 274: 1839-45.[section
1.4] [section 1.5]
[section 3.2] [section
3.3.2] [section 3.4]
[section 5.1.3]
13 Steering
Committee of the Physicians' Health Study Research Group. Final report on
the aspirin component of the ongoing Physicians' Health Study. N Engl J
Med 1989; 321: 129-35.
[section 1] [section
9]
14 Medical
Research Council's General Practice Research Framework. Thrombosis prevention
trial: randomised trial of low-intensity oral anticoagulation with warfarin
and low-dose aspirin in the primary prevention of ischaemic heart disease
in men at increased risk. Lancet 1998; 351: 233-41 [and correspondence,
1204-7].[section
1.4] [section 1.5]
[section 5] [section
9.1] [section 9.2] [section
11.1.2] [section 11.1.4]
15 Prasad
N, Srikanthan VS, Wright A, Dunn FG. Management of suspected myocardial
infarction before admission: updated audit. BMJ 1998; 316: 353.
[section 1] [section
5] [section 14]
16 ASPIRE
Steering Group. A British Cardiac Society survey of the potential for the
secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention
through Intervention to Reduce Events). Heart 1996; 75: 334-42.[section
1.4] [section 1.5] [section
14]
17 European
Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic
atrial fibrillation after transient ischaemic attack or minor stroke. Lancet
1993; 342: 1255-62.
[section 1] [section
3.2] [section
3.3.1] [section 5.1.3]
[section
7.1.1] [section 7.2.5]
18 Albers
GW. Atrial fibrillation and stroke. Three new studies, three remaining questions.
Arch Intern Med 1994; 154: 1443-8. [section
1] [section 3.2]
19 Poller
L, Hirsh J, editors. Oral anticoagulants. London: Arnold; 1996.[section
1] [section 3.2]
[section 5.1.3]
[section 8] [section
13]
20 Dolovich
L, Ginsberg JS. Low molecular weight heparin in the treatment of venous
thromboembolism: an updated meta-analysis. Vessels 1997; 3: 4-11.
[section 1] [section
2.3] [section 2.3.3] [section
12]
21 Koopman
MMW, Kraaijenhagen RA, Büller H. The feasibility of low molecular weight
heparin treatment of venous thromboembolism at home. Vessels 1997; 3: 12-17.
[section 1] [section
2]
22 Monreal
M. Long-term treatment of venous thromboembolism: the place of low molecular
weight heparin. Vessels 1997; 3: 18-21.[section
1] [section 2.3.3]
[section
2.5] [section 12]
23 Hobbs
FD, Fitzmaurice DA. Where should oral anticoagulation monitoring take place?
Br J Gen Pract 1997; 47: 479-80.
24 McInnes
GT, Helenglass G. The performance of clinics for outpatient control of anticoagulation.
J R Coll Physicians Lond 1987: 21: 42-5.
[section 1] [section
14]
25 Bath
PM, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in
patients with atrial fibrillation. BMJ 1993; 307: 1045.
[section 1] [section
14]
26 Barnaby
J, Howitt AJ. Antithrombotic treatment and atrial fibrillation. BMJ 1993;
306: 207.
[section 1] [section
14]
27 Fibrinolytic
Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic
therapy in suspected acute myocardial infarction: collaborative overview
of early mortality and major morbidity results from all randomised trials
of more than 1,000 patients [published erratum appears in Lancet 1994; 343:
742]. Lancet 1994; 343: 311-22.
[section 1] [section
5]
28 Ludlam
CA, Bennett B, Fox KA, Lowe GD, Reid AW. Guidelines for the use of thrombolytic
therapy. Haemostasis and Thrombosis Task Force of the British Committee
for Standards in Haematology. Blood Coagul Fibrinolysis 1995; 6: 273-85.
[section 1] [section
2.6.1] [section 2.6.2] [section
5.1] [section 5.1.3] [section
6.2.2]
29 Working
Party on Thrombolysis in the Management of Limb Ischaemia. Thrombolysis
in the management of limb arterial occlusion. Towards a consensus interim
report. J Intern Med 1996; 240:343-55.[section
1] [section 6.2.2]
30 Wells
PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, et al. Value of
assessment of pretest probability of deep-vein thrombosis in clinical management.
Lancet 1997; 350: 1795-8.
[section 2.2] [section
2.2.2]
31 Prins
MH, Turpie AG. Management of venous thromboembolism. In: Tooke JE, Lowe
GD, editors. A Textbook of vascular medicine. London: Arnold; 1995. p515-37.[section
2.2.1] [section 2.2.2]
[section 2.2.3] [section
2.3.1] [section 2.4.4] [section
2.6.1] [section
2.6.2]
32 Hyers
TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease.
Chest 1995; 108: 335s-351s.
[section 2.2.1] [section
2.2.3] [section 2.3] [section
2.4.1] [section 2.4.2] [section
2.4.3] [section 2.4.4] [section
2.6.1] [section
2.6.2] [section 2.6.4] [section
2.7] [section 12]
33 Bernardi
E, Prandoni P, Lensing AW, Agnelli G, Guazzacola G, Scannapieco G, et al.
D-dimer testing as an adjunct to ultrasonography in patients with clinically
suspected deep vein thrombosis: prospective cohort study. BMJ 1998; 317:
1037-40.
34 Sluzewski
M, Koopman MM, Schuur KH, Van Vroonhoven TJ, Ruijs JH. Influence of negative
ultrasound findings on the management of in- and out patients with suspected
deep-vein thrombosis. Eur J Radiol 1991; 13: 174-7.
35 Heijboer
H, Buller HR, Lensing AW, Turpie AG, Colly LP, ten Cate JW. Comparison of
real-time compression ultrasonography with impedance plethysmography for
the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl
J Med 1993; 329: 1365-9.
36 Cogo
A, Lensing AW, Koopman MM, Piovella F, Siragusa S, Wells PS, et al. Compression
ultrasonography for diagnostic management of patients with clinically suspected
deep vein thrombosis; prospective cohort study. BMJ 1998; 316: 17-20.
37 Prentice
AG, Lowe GD, Forbes CD. Diagnosis and treatment of venous thromboembolism
by consultants in Scotland. BMJ 1982; 285: 630-2
[section 2.2.2] [section
2.2.3]
38 Ramsay
LE. Impact of venography on the diagnosis and management of deep vein thrombosis.
BMJ 1983; 286: 698-9.
39 Wheeler
HB, Hirsh J, Wells P, Anderson FA Jr. Diagnostic tests for deep vein thrombosis.
Clinical usefulness depends on probability of disease. Arch Intern Med 1994;
154: 1921-8.
40 Hull
RD, Raskob GE, Ginsberg JS, Panju AA, Brill-Edwards P, Coates G, et al.
A non-invasive strategy for the treatment of patients with suspected pulmonary
embolism. Arch Intern Med 1994; 154: 289-97.
41 Cross
JJ, Kemp PM, Flower CD. Diagnostic imaging in pulmonary embolic disease.
Br J Hosp Med 1997; 58: 93-6.
42 British
Thoracic Society, Standards of Care Committee. Suspected acute pulmonary
embolism: a practical approach. Thorax 1997; 52 (suppl4): S1-S24.[section
2.3.3] [section 2.6.1]
43 Cooper
TJ, Hayward MJ, Hartog M. Survey on the use of pulmonary scintigraphy and
angiography for suspected pulmonary thromboembolism in the UK. Clin Radiol
1991; 43: 243-5
44 Bounameaux
H, Perrier A. Role of D-dimers in the exclusion of pulmonary embolism. Semin
Respir Crit Care Med 1996; 17: 31-7.
45 Barritt
DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism:
a controlled trial. Lancet 1960; 1: 1309-12.
[section 2.3] [section
2.3.1] [section 2.4]
46 Brandjes
DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol
and heparin compared with acenocoumarol alone in the initial treatment of
proximal vein thrombosis. N Engl J Med 1992; 327: 1485-9.
47 Kanis
JA. Heparin in the treatment of pulmonary thromboembolism. Thromb Diath
Haemorrh 1974; 32: 519-27.[section
2.3] [section 2.3.1]
48 Carson
JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical
course of pulmonary embolism. N Engl J Med 1992; 326: 1240-5.[section
2.3] [section 2.3.1]
[section 2.4] [section
2.4.4]
49 Weitz
JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
[section 2] [section
12]
50 The Columbus
Investigators. Low-molecular-weight heparin in the treatment of patients
with venous thromboembolism. N Engl J Med 1997; 337: 657-62[section
2.3] [section 2.3.3]
51 Simonneau
G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin
with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;
337: 663-9.
[section 2.3] [section
2.3.3]
52 Wheeler
AP, Jaquiss RDB, Newman JH. Physician practices in the treatment of pulmonary
embolism and deep vein thrombosis. Arch Intern Med 1988; 148: 1321-5.
53 Fennerty
A, Campbell IA, Routledge PA. Anticoagulants in venous thromboembolism.
BMJ 1988; 297: 1285-8
[section 2] [section
12] [section 13]
54 Hirsh
J. Heparin. NEJM 1991; 324: 1565-74.
[section 2] [section
12]
55 Hommes
DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared
with continuous intravenous heparin administration in the initial treatment
of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992; 116: 279-84.
[section 2] [section
12]
56 Prandoni
P, Bagatella P, Bernardi G, Girolami B, Rossi L, Scarana L, et al. Use of
an algorithm for administering subcutaneous heparin in the treatment of
deep venous thrombosis. Ann Intern Med 1998; 129: 299-302.
[section 2] [section
12]
57 Lagerstedt
CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long term
anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;
2: 515-8.
[section 2.4] [section
2.4.4]
58 Hull
RD, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium
versus low-dose heparin in the long term treatment of venous thrombosis.
N Engl J Med 1979; 301: 855-8.
[section 2.4] [section
2.4.1] [section
2.4.4]
59 Hull
RD, Delmore T, Carter C, Hirsh J, Genton E, Gent M, et al. Adjusted subcutaneous
heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
N Engl J Med 1982; 306: 189-94.
[section 2.4] [section
2.4.1] [section
2.4.4] [section 2.5]
60 Hull
RD, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities
of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.
N Engl J Med 1982; 307: 1676-81.
[section 2.4] [section
2.4.1] [section
2.4.4]
61 Coon
WW, Willis PW. Recurrence of venous thromboembolism. Surgery 1973; 73: 823-7.
[section 2.4] [section
2.4.4]
62 Gallus
A, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin
started early after submassive venous thrombosis or pulmonary embolism.
Lancet 1986; 2: 1293-6.
[section 2.4.1] [section
2.4.3] [section
2.4.4]
63 Hull
RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, et
al. Heparin for 5 days as compared with 10 days in the initial treatment
of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-4.[section
2.4.1] [section 2.4.3]
[section
2.4.4]
64 Mohiuddin
SM, Hilleman DE, Destache CJ, Stoysich AM, Gannon JM, Sketch MH Sr. Efficacy
and safety of early versus late initiation of warfarin during heparin therapy
in acute thromboembolism. Am Heart J 1992; 123: 729-32.[section
2.4.1] [section 2.4.3]
[section
2.4.4]
65 Schulman
S, Lockner D. Relationship between thromboembolic complications and intensity
of treatment during long term prophylaxis with oral anticoagulants following
DVT. Thromb Haemost 1985; 53: 137-40.
[section 2.4.1] [section
2.4.4]
66 Geerts
WH, Jay RM. Oral anticoagulants in the prevention and treatment of venous
thromboembolism. In: Poller J, Hirsh J, editors. Oral Anticoagulants. London:
Arnold; 1996. p97-122.
[section 2.4.1] [section
2.4.4] [section
2.6.1] [section
2.6.2] [section 2.7]
67 Palareti
G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding
complications of oral anticoagulant treatment: an inception-cohort, prospective
collaborative study. Italian Study on Complications of Oral Anticoagulant
Therapy (ISCOAT). Lancet 1996; 348: 423-8.
68 British
Thoracic Society. Optimum duration of anticoagulation for deep vein thrombosis
and pulmonary embolism. Lancet 1992; 340: 873-6.
69 Prandoni
P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term
clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:
1-7.
[section 2.4.4] [section
2.7]
70 Maternal
and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis
Task Force. British Society for Haematology guidelines on the prevention,
investigation and management of thrombosis associated with pregnancy. J
Clin Pathol 1993; 46: 489-96.
[section 2.5] [section
2.9] [section
4.7]
71 Decousus
H, Leizerovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical
trial of vena caval filters in the prevention of pulmonary embolism in patients
with proximal deep-vein thrombosis. N Engl J Med 1998; 338: 409-15.
72 Brandjes
DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al. Randomised
trial of effect of compression stockings in patients with symptomatic proximal-vein
thrombosis. Lancet 1997; 349: 759-62.
73 The British
Committee for Standards in Haematology. Guidelines on the investigation
and management of thrombophilia. J Clin Pathol 1990; 43: 703-9.
[section 2] [section
8] [section 13]
74 Lowe
GD, Rumley A, Woodward M, Reid E. Epidemiology of activated protein C resistance,
APTT and Factor V Leiden: the Glasgow MONICA study. Blood Coag Fibrinolys
1997; 8: 463.
75 Sarasin
FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant
treatment in factor V Leiden carriers with first episode of deep vein thrombosis.
BMJ 1998; 316: 95-9.
76 Baglin
C, Brown K, Luddington R, Baglin T. Risk of recurrent venous thromboembolism
in patients with factor V Leiden (FVR 506Q) mutation: effect of warfarin
and prediction by precipitating factors. East Anglian Thrombophilia Study
Group. Br J Haematol 1998; 100: 764-8.
77 Lowe
GD, Jaap AJ, Forbes CD. Relationship of atrial fibrillation and high haematocrit
to mortality in acute stroke. Lancet 1983; 1: 784-6.
78 Sandercock
P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al. Atrial fibrillation
and stroke: prevalence in different types of stroke and influence on early
and long term prognosis. BMJ 1992; 305: 1460-5.
79 Royal
College of Physicians of Edinburgh Consensus Conference on Atrial Fibrillation
in Hospital and General Practice. Consensus Statement. Proc R Coll Physicians
Edinb 1998; 28: 552-4. [Unpublished background papers were also consulted.]
[section 3.1] [section
3.2] [section
3.3.1] [section 3.5]
80 Stroke
Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin
versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients
with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised
clinical trial. Lancet 1996; 348: 633-8.
81 Stroke
Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin
for prevention of thromboembolism in atrial fibrillation: Stroke Prevention
in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91. [section
3.2] [section 3.3.4]
82 Laupacis
A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy
in atrial fibrillation. Chest 1995; 108: 352s-359s.
[section 3.2] [section
3.3.2] [section
3.5] [section 4]
83 Green
CJ, Hadorn DC, Bassett K, Kazanjian A. Anticoagulation in chronic nonvalvular
atrial fibrillation: A critical appraisal and meta-analysis. Can J Cardiol
1997; 13: 811-5.
[section 3.2] [section
3.3.1]
84 Levine
HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart disease.
Chest 1995; 108: 360s-370s.
[section 3] [section
4] [section 4.1] [section
4.2] [section
4.7]
85 Stein
PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic
therapy in patients with mechanical and biological prosthetic heart valves
[published erratum appears in Chest 1996; 109: 592]. Chest 1995; 108: 371s-379s.
[section 3] [section
4] [section 4.1]
[section 4.2] [section
4.4] [section 4.5] [section
4.7]
86 Ad Hoc
Committee of the Working Group on Valvular Heart Disease, European Society
of Cardiology. Guidelines for prevention of thromboembolic events in valvular
heart disease. J Heart Valve Dis 1993; 2: 398-410.
[section 3.3.3] [section
3.5] [section 4]
[section 4.1] [section
4.2] [section 4.4]
[section
4.5] [section 4.6] [section
4.7]
87 Bjerkelund
CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism
related to DC electrical conversion of atrial fibrillation. Am J Cardiol
1969; 23: 208-16.
88 Baker
DW, Wright RF. Management of heart failure IV. Anticoagulation for patients
with heart failure due to left ventricular systolic dysfunction. JAMA 1994;
272: 1614-8.
89 Scottish
Intercollegiate Guidelines Network (SIGN). Diagnosis
and Treatment of Heart Failure due to Left Ventricular Systolic Dysfunction.
A national clinical guideline. Edinburgh: SIGN, 1999. (SIGN publication
no. 35).
90 Turpie
AG, Gent M, Laupacis A, Latour Y, Guntensen J, Basile F, et al. A comparison
of aspirin with placebo in patients treated with warfarin after heart-valve
replacement. N Engl J Med 1993; 329: 524-9.
[section 4.4] [section
4.5]
91 Second
International Study of Infarct Survival Collaborative Group. Randomised
trial of intravenous streptokinase, oral aspirin, both, or neither among
17,187 cases of suspected acute myocardial infarction: ISIS-2 Collaborative
Group. Lancet 1988; 2: 349-60.
[section 5.1] [section
5.1.1]
92 Cairns
JA, Lewis HD Jr, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in
coronary artery disease. Chest 1995; 108; 380s-400s. [section
5.1] [section 5.1.3]
[section 5.2] [section
5.3] [section 11]
93 CAPRIE
Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin
in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
[section
5.1] [section 5.1.3]
[section 6] [section
7] [section 11]
94 Yusuf
S, Michaelis W, Hua A, et al. Effects of oral anticoagulants on mortality,
reinfarction and stroke after myocardial infarction. Circulation 1995; 92,
supplement 1: 343.[section
5.1] [section 5.1.3]
95 The EPSIM
Research Group. A controlled comparison of aspirin and oral anticoagulants
in prevention of death after myocardial infarction. N Eng J Med 1982; 307:
701-8.
[section 5.1] [section
5.1.3]
96 Breddin
K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial
infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon.
Haemostasis 1980; 9: 325-44.[section
5.1] [section 5.1.3]
97 ASPECT
Research Group. Effect of long-term oral anticoagulant treatment on mortality
and cardiovascular morbidity after myocardial infarction. Anticoagulants
in the Secondary Prevention of Events in Coronary Thrombosis Research Group.
Lancet 1994; 343: 499-503.
[section
5.1] [section 5.1.3]
98 Meijer
A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ. Aspirin
versus coumadin in the prevention of reocclusion and recurrent ischaemia
after successful thrombolysis: a prospective placebo-controlled angiographic
study. Results of the APRICOT Study. Circulation 1993; 87: 1524-30. [section
5.1] [section 5.1.3]
99 Julian
DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation
following thrombolysis for myocardial infarction (the AFTER Study): a multicentre
unblinded randomised clinical trial. BMJ 1996; 313: 1429-31.[section
5.1] [section 5.1.3]
100 Cairns
JA, Fuster V, Gore J, Kennedy JW. Coronary thrombolysis. Chest 1995; 108:
401s-423s.
[section 5.1.2] [section
5.1.3]
101 Collins
R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical
effects of anticoagulant therapy in suspected acute myocardial infarction:
systematic overview of randomised trials. BMJ 1996; 313: 652-9.
102 Flaker
GC, Bartolozzi J, Davis V, McCabe C, Cannon CP. Use of a standardized heparin
nomogram to achieve therapeutic anticoagulation after thrombolytic therapy
in myocardial infarction. TIMI 4 investigators (Thrombolysis in Myocardial
Infarction). Arch Intern Med 1994; 154: 1492-6.
103 Oler
A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence
of myocardial infarction and death in patients with unstable angina. A meta-analysis.
JAMA 1996; 276: 811-5.
104 FRISC
Study Group. Low-molecular-weight heparin during instability in coronary
artery disease. Fragmin during Instability in Coronary Artery Disease (FRISC)
Study Group. Lancet 1996; 347: 561-8.
105 Cohen
M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison
of low-molecular-weight heparin with unfractionated heparin for unstable
coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin
in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.[section
5.2] [section 5.4]
106 Fox
KA, Bosanquet N. Assessing the UK cost implications of the use of low molecular
weight heparin in unstable coronary artery disease. Br J Cardiol 1998; 5:
92-105.
107 Verheugt
FW. In search of a superaspirin for the heart. Lancet 1997; 349: 1409-10
(see also 1422-35).
108 Randomised
placebo-controlled trial of eptifibatide on complications of percutaneous
coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-8.
109 Randomised
placebo-controlled trial of abciximab before and during coronary intervention
in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
110 Moliterno
DJ, Sapp SK, Topol EJ. The paradoxical effect of thrombolytic therapy for
unstable angina: meta-analysis. J Am Coll Cardiol 1994; 23: 288A.
111 Stein
PD, Dalen JE, Goldman S, Schwartz L, Theroux P, Turpie AG. Antithrombotic
therapy in patients with saphenous vein and internal mammary artery bypass
grafts. Chest 1995; 108: 424s-430s.
112 Popma
JJ, Coller BS, Ohman EM, Bittl JA, Weitz J, Kuntz RE, et al. Antithrombotic
therapy in patients undergoing coronary angioplasty. Chest 1995; 108: 486s-501s.
113 More
RS, Chauhan A. Antiplatelet rather than anticoagulant therapy with coronary
stenting. Lancet 1997; 349: 146-7.
114 Scottish
Intercollegiate Guidelines Network (SIGN). Coronary
Revascularisation in the Management of Stable Angina Pectoris. A national
clinical guideline. Edinburgh: SIGN, 1998. (SIGN publication no. 32.)
115 Goldhaber
SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE, et al. Low-dose
aspirin and subsequent peripheral arterial surgery in the Physician's Health
Study. Lancet 1992; 340: 143-5.
116 Clagett
GP, Krupski WC. Antithrombotic therapy in peripheral arterial occlusive
disease. Chest 1995; 108: 431s-443s.
[section 6.1] [section
6.2] [section 6.2.2]
[section 6.3]
117 Scottish
Intercollegiate Guidelines Network (SIGN). Drug
Therapy for Peripheral Vascular Disease. Edinburgh: SIGN, 1998. (SIGN
publication no. 27.)
118 Tangelder
M, Algra A, Lawson J, Eikelboom B. Improving patency and reducing morbidity
and mortality after lower extremity bypass surgery: oral anticoagulants
or aspirin? Critical Ischaemia 1998; 7: 68-76.[section
6.1] [section 6.3]
119 European
Working Group on Critical Limb Ischaemia. Second European consensus document
on chronic critical leg ischaemia. Circulation 1991; 84, Supplement IV:
1-26.
[section
6.2] [section
6.2.2]
120 Ouriel
K, Shortell CK, DeWeese JA, Green RM, Francis CW, Azodo MV, et al. A comparison
of thrombolytic therapy with operative revascularization in the initial
treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19: 1021-30.
121 The
STILE Investigators. Results of a prospective randomized trial evaluating
surgery versus thrombolysis for ischaemia of the lower extremity. Ann Surg
1994; 220: 251-66.
122 Ouriel
K, Veith F, Sasahara AA.A comparison of recombinant urokinase with vascular
surgery as initial treatment for acute arterial occlusion of the legs. N
Engl J Med 1998; 338: 1105-11.
123 Verstraete
M. Thombolysis in the management of lower limb peripheral arterial occlusion
- a consensus document. Am J Cardiol 1998; 81: 207-18.
124 Scottish
Intercollegiate Guidelines Network (SIGN). Management
of patients with stroke. I: Assessment, investigation, immediate management
and secondary prevention. Edinburgh: SIGN, 1997. (SIGN publication no.
13.)
[section 7.1.1] [section
7.1.2] [section 7.2.1] [section
7.2.5]
125 The
International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous
heparin, both, or neither among 19,435 patients with acute ischaemic stroke.
International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-81.
[section 7.1.1] [section
7.1.2]
126 CAST
(Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled
trial of early aspirin use in 20,000 patients with acute ischaemic stroke.
Lancet 1997; 349: 1641-9.
[section 7.1.1] [section
7.1.2]
127 Weir
CJ, Murray GD, Adams FG, Muir KW, Grosset DG, Lees KR. Poor accuracy of
stroke scoring systems for differential clinical diagnosis of intracranial
haemorrhage and infarction. Lancet 1994; 344: 999-1002.
128 Sherman
DG, Dyken ML Jr, Gent M, Harrison JG, Hart RG, Mohr JP. Antithrombotic therapy
for cerebrovascular disorders. An update. Chest 1995; 108: 444s-456s.
129 Diener
HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke
Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary
prevention of stroke. J Neurol Sci 1996; 143: 1-13.
[section 7] [section
11]
130 European
Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 1997;
151: 1s-77s.
131 Jonas
S. Anticoagulant therapy in cerebrovascular disease: a review and meta-analysis.
Stroke 1988; 19: 1043-8.
132 Stroke
Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized
trial of anticoagulants versus aspirin after cerebral ischemia of presumed
arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT)
Study Group. Am Neurol 1997; 42: 857-65.
133 Scottish
Intercollegiate Guidelines Network (SIGN). Management
of patients with stroke. II: Management of carotid stenosis and carotid
endarterectomy. Edinburgh: SIGN, 1997. (SIGN publication no. 14.)
134 British
Committee for Standards in Haematology, Haemostasis and Thrombosis Task
Force. Guidelines on oral anticoagulation: third edition. Br J Haematol
1998; 101: 374-87.
[section 8] [section
13.1] [section 13.3]
135 Hansson
L, Zanchetti A, Carruthers, SG, Dahlöf, Elmfeldt D, Julius S, et al.
Effects of intensive blood pressure lowering and low-dose aspirin in patients
with hypertension: principal results of the Hypertension Optimal Treatment
(HOT) randomised trial. Lancet 1998; 351: 1755-62.
136 Verheught
FW. Aspirin, the poor man's statin? Lancet 1998; 351: 227-8.
137 Dyslipidaemia
Advisory group, on behalf of the scientific committee of the National Heart
Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines
for the assessment and management of dyslipidaemia. NZ Med J 1996; 109:
224-31.
138 Scotttish
Intercollegiate Guidelines Network (SIGN). Lipids
and the Primary Prevention of Coronary Heart Disease. SIGN, Edinburgh
1998.
139 Bambauer
R, Rucker S, Weber U, Kohler M. Comparison of low molecular weight heparin
and standard heparin in hemodialysis. ASAIO Trans 1990; 36: 646-9.
140 Randolph
AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in peripheral venous
and arterial catheters: systematic review and meta-analysis of randomised
controlled trials. BMJ 1998; 316: 969-75.
141 Bern
MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, et al. Very
low doses of warfarin can prevent thrombosis in central venous catheters.
A randomized prospective trial. Ann Intern Med 1990; 112: 423-8.
142 Levine
M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomized
trial of very low-dose warfarin for prevention of thromboembolism in stage
IV breast cancer. Lancet 1994; 343: 886-9.
143 Hirsh
J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active
drugs. The relationship among dose, effectiveness and side-effects. Chest
1995; 108: 247s-257s.
[section 11.1.1] [section
11.1.2] [section 11.1.4] [section
11.3]
144 Evans
JM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, et al. Non-steroidal
anti-inflammatory drugs and hospitalisation for acute renal failure. QJM
1995; 88: 551-7.
145 He
J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke. A
meta-analysis of randomised controlled trials. JAMA 1998; 280: 1930-5.
146 Weil
J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic
aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
147 Roderick
PJ, Wickes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview
of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219-26.
148 Kelly
JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated
major upper-gastrointestinal bleeding with enteric-coated or buffered product.
Lancet 1996; 348: 1413-6.
149 Meade
TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extra-cranial bleeding
and other symptoms due to low dose aspirin and low intensity oral anticoagulation.
Thromb Haemost 1992; 68: 1-6.
[section 11] [section
13]
150 British
Committee for Standards in Haematology, Working Party of the Blood Transfusion
Task Force. Guidelines for platelet transfusions. Transfus Med 1992; 2:
311-8.
151 Hawkey
CJ. Drug-induced gastrointestinal disorders. Medicine 1998; 26(10): 122-5.
152 Hirsh
J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism
of action, pharmacokinetics, dosing considerations, monitoring, efficacy,
and safety. Chest 1995; 108: 258s-275s.
[section 12.1] [section
12.1.1] [section 12.2]
153 Levine
MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant
treatment. Chest 1995; 108: 276s-290s.
154 British
National Formulary. London: BMA; 1998.
[section 12] [section
13]
155 Boneu
B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost
1994; 72: 330-4.
156 Scottish
Intercollegiate Guidelines Network (SIGN). Helicobacter
Pylori: Eradication Therapy in Dyspeptic Disease. SIGN, Edinburgh 1996.
157 Tait
RC, Sefcick A. A warfarin induction regimen for out-patient anticoagulation
in patients with atrial fibrillation. Br J Haematol 1998; 101: 450-4.
158 Oates
A, Jackson PR, Austin CA, Channer KS. A new regimen for starting warfarin
in out-patients. Br J Clin Pharmacol 1998; 46: 157-61.
159 Bussey
HI, Chiquette E, Amato MG. Anticoagulation clinic care versus routine medical
care: a review and interim report. J Thrombos Trombolys 1996; 2: 315-9.
[section 13] [section
14]
160 Poller
L, Shiach CR, MacCallum PK, Johansen AM, Münste AM, Magalhâes
A, et al. Multicentre randomised study of computerised anticoagulant dosage.
Lancet 1998; 352: 1505-9.
[section 13] [section
14]
161 Shetty
HGM, Routledge PA. Computer-assisted anticoagulation. In Verstraete M, Fuster
V, Topol EJ, editors. Cardiovascular thrombosis: Thrombocardiology and thromboneurology.
2nd ed. Philadelphia Lippincott; 1998. P.843-9.
162 Bernardo
A. Experience with patient self-management of oral anticoagulation. J Thrombos
Thrombolys 1996; 2: 321-5.
163 Joint
Working Group on Quality Assurance. Guidelines on the control of near-patient
tests and procedures performed on patients by non-pathology staff. In: Roberts
BE, Wood K, editors. Standard haematology practice. 2nd ed. Oxford: Blackwell
Science; 1994. p278-9.
164 Cortelazzo
S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, et al. Thrombotic
and hemorrhagic complications in patients with mechanical heart valve prosthesis
attending an anticoagulation clinic. Thromb Haemost 1993; 69: 316-20.
165 Katsuki
T, Saito M, Noda T, Yaginuma T, Hosoda S. Long-term follow-up in patients
receiving anticoagulation therapy: potency of therapy and complications.
J Cardiol 1994; 24: 203-9.
166 Hylek
EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking
warfarin. Ann Intern Med 1994; 120: 897-902.
167 Fihn
SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors
for complications of chronic anticoagulation. A multicenter study. Warfarin
optimized outpatient follow-up study group. Ann Intern Med 1993; 118: 511-20.
168 Franke
CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral
hematomas during anticoagulant treatment. Stroke 1990; 21: 726-30.
169 Routledge
PA. Management of bleeding induced by oral anticoagulants. Prescr Journal
1993; 33: 59-63.
170 Shetty
HG, Backhouse G, Bentley DP, Routledge PA. Effective reversal of warfarin-induced
excessive anticoagulation with low dose vitamin K1. Thromb Haemost 1992;
67: 13-5.
171 Taberner
DA, Thomson JM, Poller L. Comparison of prothrombin complex concentrate
and vitamin K1 in oral anticoagulant reversal. BMJ 1976; 2: 83-5.
172 Andersen
P, Godal HC. Predictable reduction in anticoagulant activity of warfarin
by small amounts of vitamin K. Acta Med Scand 1975; 198: 269-70.
173 Pengo
V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect
of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared
with warfarin discontinuation. Blood Coagul Fibrinolys 1993; 4: 739-41.
174 Park
BK, Scott AK, Wilson AC, Haynes BP, Breckenridge AM. Plasma disposition
of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol
1984; 18: 655-62.
175 Fredriksson
K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after
intracerebral hemorrhage. Stroke 1992; 23: 972-7.
176 Makris
M, Greaves M, Philips WS, Kitchen S, Rosendaal FR, Preston FE. Emergency
oral anticoagulant reversal: the relative efficacy of infusions of fresh
frozen plasma and clotting factor concentrate on correction of the coagulopathy.
Thromb Haemost 1997; 77: 477-80.
177 Loken
S, Allen JE, Stults BM. Special problems in anticoagulation therapy: cancer
and venous thromboembolism-temporary discontinuation of warfarin for surgery
and invasive procedures. J Thrombos Trombolys 1996; 2: 289-93.
178 Kearon
C, Hirsh J. Management of anticoagulation before and after elective surgery.
N Engl J Med 1997; 336: 1506-11.
179 Parekh
R, Ghee C. Evaluation of a pharmacist controlled anticoagulation clinic.
Br J Pharm Pract 1987; 9: 370-81.
[section 13] [section
14]
180 Garabedian-Ruffalo
SM, Gray DR, Sax MJ, Ruffalo RL. Retrospective evaluation of a pharmacist-managed
warfarin anticoagulation clinic. Am J Hosp Pharm 1985; 42: 304-8.
[section 13] [section
14]
181 Radely
SA, Hall J. The establishment and evaluation of a pharmacist-developed anticoagulation
clinic. Pharmaceut J 1994; 252: 91-2.
[section 13] [section
14]
182 Simmans
A. Run an anticoagulation clinic. A pharmacy managed anticoagulation clinic:
The Airedale Experience. Hosp Pharm Pract 1994; 4: 151-6.
[section 13] [section
14]
183 Tan
G, Cohen H, Taylor F, Gabbay J. Audit of start of anticoagulation treatment
in inpatients. J Clin Pathol 1993; 46: 67-71.
[section 14] [section
15] [annex 1] [annex
2]
184 Taylor
F, Ramsay M, Renton A, Cohen H. Guidelines for anticoagulation. BMJ 1994;
309: 197.
[section 14.4] [section
14.5] [section 15.1.1] [section
15.1.2]
185 Sudlow
M, Rodgers H, Kenny RA, Thomson R. Population based study of use of anticoagulants
among patients with atrial fibrillation in the community. BMJ 1997; 314:
1529-30.
186 Sudlow
M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation
and eligibility for anticoagulants in the community. Lancet 1998; 352: 1167-71.
![[Contents]](../../../images/contents.gif){kind=small}
![[Back]](../../../images/back.gif){kind=small}
![[Top]](../../../images/top.gif){kind=small}